Exin Therapeutics AI agent picks, delivers gene therapy into living mouse brain
In brief
- Exin says its AI agent reviewed 19 candidate gene therapies and chose one designed to boost GABA.
- 250 nanoliters went in over five minutes, delivered by the agent through a motorized stereotaxic rig.
- Human surgeon performed the craniotomy; a licensed veterinarian held a physical kill switch.
- Exin calls the run a demonstration; its product is the CircuitATLAS drug-discovery platform.
What the agent actually did
The details come from posts Ocana-Santero shared on social media, as reported by Crypto Briefing. According to those posts, the agent reviewed 19 candidate gene therapies and picked one designed to boost GABA. The test subject was a mouse model of epilepsy. The agent chose the lateral entorhinal cortex as its target, then drew on scientific literature to calculate injection coordinates (3.90 mm behind bregma, 4.00 mm to the right and 4.30 mm down).
Those coordinates went into a motorized stereotaxic rig. With the mouse anesthetized, the agent delivered 250 nanoliters of the therapy over five minutes. Ocana-Santero also pointed to the agent's job of watching for complications such as bleeding.
It wasn't an autonomous surgery.
A human surgeon performed the craniotomy and closed the mouse up afterward, while the agent handled targeting, delivery and monitoring. A licensed veterinarian supervised and held a physical kill switch that could stop the rig instantly. Crypto Briefing said the procedure needed extra steps and a lot of human supervision. The outlet also cited unnamed accounts describing moments when human operators tried to override the agent's decisions and the agent held to its protocols. Those accounts weren't tied to a named source.
Why Exin wants agents in the lab
Exin is a San Francisco biotech startup in Y Combinator's Winter 2025 cohort. Ocana-Santero co-founded it with Marko Tvrdic, and the company focuses on AI-driven treatments for neurological conditions.
“We’ve realized that we need to connect these agents to a lab to get the maximum value from them,” Ocana-Santero said, according to Crypto Briefing.
The mouse injection is a demonstration, not a product. Exin's actual product is CircuitATLAS, a platform that pairs systems neuroscience knowledge with agentic reasoning (AI that can plan and take multi-step actions). It's aimed at drug discovery for targeted therapies across neurological disorders.
The Philippines lab
Part of that work runs through a neurotherapeutics lab in the Philippines, where Crypto Briefing reported Exin has invested approximately $25 million. The company is also generating its own data and developing patented technologies, according to the same report.
Frequently asked questions
Was Exin's AI-guided mouse brain injection fully autonomous?
No. A human surgeon performed the craniotomy and closed the mouse afterward, while the AI agent handled targeting, delivery and monitoring. A licensed veterinarian supervised the procedure and held a physical kill switch that could stop the rig instantly.
What is Exin Therapeutics' CircuitATLAS platform?
CircuitATLAS is the product Exin is building. It pairs systems neuroscience knowledge with agentic reasoning and is aimed at drug discovery for targeted therapies across neurological disorders. The mouse injection was a demonstration, not the product itself.
